Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Guttman

Showing results (121-130 of 387) with videos related to

Pageof 39
Sort By:
Archives of Dermatological Research|November 6, 2024
Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimabEmma Guttman-Yassky, Ehsanollah Esfandiari, Hirotaka Mano, et al.
JAMA Dermatology|February 27, 2020
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical TrialEmma Guttman-Yassky, Andrew Blauvelt, Lawrence F Eichenfield, et al.
The Journal of Dermatological Treatment|May 21, 2026
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitisEmma Guttman-Yassky, Thomas Bieber, Kenji Kabashima, et al.
The Journal of Allergy and Clinical Immunology|June 20, 2013
Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitisMayte Suárez-Fariñas, Nikhil Dhingra, Julia Gittler, et al.
The Journal of Allergy and Clinical Immunology|June 16, 2018
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAbAndreas Wollenberg, Michael D Howell, Emma Guttman-Yassky, et al.
JID Innovations : Skin Science From Molecules to Population Health|October 24, 2022
Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a TrialBrett King, Emma Guttman-Yassky, Elena Peeva, et al.
Archives of Dermatological Research|August 20, 2018
Efficacy and safety of secukinumab treatment in adults with extensive alopecia areataEmma Guttman-Yassky, John K Nia, Peter W Hashim, et al.
Journal of Drugs in Dermatology : JDD|February 6, 2025
Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial GroupsEmma Guttman-Yassky, Norito Katoh, Michael J Cork, et al.
The Journal of Allergy and Clinical Immunology|August 3, 2023
The role of Janus kinase signaling in the pathology of atopic dermatitisEmma Guttman-Yassky, Alan D Irvine, Patrick M Brunner, et al.
International Journal of Dermatology|February 27, 2016
Use of 308 nm excimer laser for the treatment of chronic hand and foot eczemaAnjali Shroff, Dana Malajian, Tali Czarnowicki, et al.
Pageof 39

Showing results (121-130 of 387) with videos related to

Sort By:
Pageof 39
Archives of Dermatological Research|November 6, 2024
Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimabEmma Guttman-Yassky, Ehsanollah Esfandiari, Hirotaka Mano, et al.
JAMA Dermatology|February 27, 2020
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical TrialEmma Guttman-Yassky, Andrew Blauvelt, Lawrence F Eichenfield, et al.
The Journal of Dermatological Treatment|May 21, 2026
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitisEmma Guttman-Yassky, Thomas Bieber, Kenji Kabashima, et al.
The Journal of Allergy and Clinical Immunology|June 20, 2013
Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitisMayte Suárez-Fariñas, Nikhil Dhingra, Julia Gittler, et al.
The Journal of Allergy and Clinical Immunology|June 16, 2018
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAbAndreas Wollenberg, Michael D Howell, Emma Guttman-Yassky, et al.
JID Innovations : Skin Science From Molecules to Population Health|October 24, 2022
Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a TrialBrett King, Emma Guttman-Yassky, Elena Peeva, et al.
Archives of Dermatological Research|August 20, 2018
Efficacy and safety of secukinumab treatment in adults with extensive alopecia areataEmma Guttman-Yassky, John K Nia, Peter W Hashim, et al.
Journal of Drugs in Dermatology : JDD|February 6, 2025
Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial GroupsEmma Guttman-Yassky, Norito Katoh, Michael J Cork, et al.
The Journal of Allergy and Clinical Immunology|August 3, 2023
The role of Janus kinase signaling in the pathology of atopic dermatitisEmma Guttman-Yassky, Alan D Irvine, Patrick M Brunner, et al.
International Journal of Dermatology|February 27, 2016
Use of 308 nm excimer laser for the treatment of chronic hand and foot eczemaAnjali Shroff, Dana Malajian, Tali Czarnowicki, et al.
Pageof 39